ANDROID 10 Drug Patent Profile
Which patents cover Android 10, and when can generic versions of Android 10 launch?
Android 10 is a drug marketed by Valeant Pharms North and is included in one NDA.
The generic ingredient in ANDROID 10 is methyltestosterone. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the methyltestosterone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Android 10
A generic version of ANDROID 10 was approved as methyltestosterone by IMPAX LABS on December 31st, 1969.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ANDROID 10?
- What are the global sales for ANDROID 10?
- What is Average Wholesale Price for ANDROID 10?
Summary for ANDROID 10
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 49 |
| Clinical Trials: | 10 |
| Patent Applications: | 4,217 |
| DailyMed Link: | ANDROID 10 at DailyMed |
Recent Clinical Trials for ANDROID 10
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| St. Olavs Hospital | Phase 4 |
| Oslo University Hospital | Phase 4 |
| Haukeland University Hospital | Phase 4 |
US Patents and Regulatory Information for ANDROID 10
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valeant Pharms North | ANDROID 10 | methyltestosterone | TABLET;ORAL | 086450-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
